UroGen Pharma (NASDAQ:URGN) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Kate Bechtold - Director, Corporate Communications and Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Ram Selvaraju - H. C. Wainwright Boris Peaker - Cowen Leland Gershell - Oppenheimer Chris Howerton - Jefferies Operator Good morning, ladies and gentlemen. Thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. Indicate by check mark ...